Search Results

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that it has closed on $4.3 million in a financing led by CJC Investment Trust, an entity controlled by board member Christopher Calise.

The genome editing market size reached US$ 8.03 billion in 2023 and is projected to grow to around US$ 38.43 billion by 2033, with a CAGR of 16.95% during the forecast period from 2024 to 2033.

Illumina Inc., a global leader in DNA sequencing and array-based technologies, announced the launch of DRAGEN™ v4.3, the latest version of its DRAGEN™ software, part of the Illumina Connected Software portfolio, for analysis of next-generation sequencing data.

The direct-to-consumer genetic testing market size is expected to be worth around USD 17.35 billion by 2033 and growing at a CAGR of 24.43% from 2024 to 2033, according to Vision Research Reports.

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper) today announced that management will present at the 43rd Annual TD Cowen Healthcare Conference at 10:30am EST on March 4, 2024.

QurAlis Corporation today announced it will present preclinical data showing that TDP-43 (TAR DNA-binding protein 43) pathology drives loss of synaptic UNC13A function in neurodegenerative diseases including ALS and FTD.

Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.

Aptose Biosciences Inc. today announced that it has entered into a definitive agreement for the issuance and sale of 3,855,000 of its common shares (or common share equivalents in lieu thereof) at a purchase price of $1.15 per share.

Aptose Biosciences Inc. announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,855,000 of its common shares at a purchase price of $1.15 per share.